Bharat Biotech

Rs 150 per dose is not sustainable in long run: Bharat Biotech on Centre's Covaxin price

The company said, as directed by the Government of India, less than 10 per cent of the total production of Covaxin to date has been supplied to private hospitals.

published on : 15th June 2021

Covaxin's emergency nod push in US fails

No vaccine manufactured or developed from India has ever received emergency use authorisation or full licensure from USFDA.

published on : 12th June 2021

US FDA rejects emergency authorisation for Covaxin, 'recommends' to take full approval route

Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission.

published on : 11th June 2021

Another 44 crore Covid vaccines ordered, 2.16 billion doses by December-end is the promise 

With the latest purchase orders, the government has secured 74 crore coronavirus vaccine doses for the country from August onwards, announced V K Paul.

published on : 8th June 2021

Ocugen pays USD 15 million upfront to Bharat Biotech for Covaxin rights in Canada

Ocugen in a regulatory filing said it has agreed to pay another USD 10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country.

published on : 8th June 2021

Decks cleared for import of Bharat Biotech's Covaxin, Russia's Sputnik V into Brazil, conditions apply

According to Anvisa's approval, Brazil is expected to receive four million doses of Covaxin initially.

published on : 6th June 2021

‘Manufacturer didn’t meet commitment’: Kejriwal government to HC on Covaxin shortage in national capital

The court said that the Delhi government should have stopped providing people with the first dose of Covaxin when it realised that it will not be getting any more supplies from Bharat Biotech.

published on : 5th June 2021

Data sharing going on with WHO to give recognition to Covaxin: Govt

Responding to a question on recognition of Covaxin by the WHO, NITI Aayog Member (Health) V K Paul said the government is pursuing it.

published on : 4th June 2021

Bharat Biotech bypasses red tape, gets KSPCB nod for Covaxin production

Pharma firm will now produce Covaxin vials from existing Biovet facility at Malur  

published on : 4th June 2021

TN, Bharat Biotech discuss Covid vaccine unit set up

Amid shortage of vaccines, the State government has started the process to woo manufacturers to set up their units in Tamil Nadu.

published on : 4th June 2021

Haffkine to start manufacturing 22.8 crore Covaxin doses from February 2022

The vaccine production process involves two stages – drug substance and final drug product, the official explained.

published on : 3rd June 2021

3.11 crore doses of Covaxin procured so far, 90 lakh doses expected in June: Centre

It said that the current production capacity of Covaxin, which is 1 crore per month, will be doubled by May-June and then increased 6-7 fold by July – August.

published on : 28th May 2021

'Covaxin has a production cycle of 120 days': Bharat Biotech on delayed availability of vaccine

Experts said that the statement by Bharat Biotech may further heighten the confusion around vaccine availability rather than clearing the air.

published on : 28th May 2021

Covaxin manufacturing to vaccination takes four months, says Bharat Biotech

Bharat Biotech's clarification comes at a time when the country is facing a shortage of COVID-19 vaccines, leading to disruptions in the nationwide inoculation programme.

published on : 28th May 2021

ICMR to examine effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin

The government has been stressing on the need to wear a mask and adherence to other coronavirus protocols.

published on : 26th May 2021
1 2 3 4 5 6 >